Traders sold shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) on strength during trading on Monday following insider selling activity. $34.96 million flowed into the stock on the tick-up and $46.17 million flowed out of the stock on the tick-down, for a money net flow of $11.21 million out of the stock. Of all stocks tracked, Vertex Pharmaceuticals had the 22nd highest net out-flow for the day. Vertex Pharmaceuticals traded up $1.27 for the day and closed at $80.50Specifically, Director Joshua S. Boger sold 6,500 shares of the stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $95.93, for a total value of $623,545.00. Following the completion of the sale, the director now owns 274,725 shares of the company’s stock, valued at $26,354,369.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joshua S. Boger sold 47,000 shares of the stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $100.66, for a total transaction of $4,731,020.00. Following the completion of the sale, the director now directly owns 274,725 shares of the company’s stock, valued at approximately $27,653,818.50. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by insiders.

VRTX has been the subject of several analyst reports. RBC Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 12th. Jefferies Group restated a “buy” rating and issued a $104.00 target price on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 12th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 5th. Leerink Swann restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, September 30th. Finally, Robert W. Baird restated a “neutral” rating and issued a $115.00 target price (down from $128.00) on shares of Vertex Pharmaceuticals in a research note on Friday, September 30th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $117.60.

The firm’s 50-day moving average is $90.31 and its 200-day moving average is $89.75. The firm’s market capitalization is $19.95 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.03. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. The firm had revenue of $431.61 million for the quarter, compared to the consensus estimate of $428.08 million. During the same quarter in the previous year, the company earned ($0.54) earnings per share. The business’s revenue was up 159.9% compared to the same quarter last year. Equities research analysts expect that Vertex Pharmaceuticals Inc. will post $0.89 earnings per share for the current year.

Several large investors have recently modified their holdings of VRTX. National Pension Service increased its stake in shares of Vertex Pharmaceuticals by 8.9% in the third quarter. National Pension Service now owns 179,978 shares of the pharmaceutical company’s stock valued at $15,696,000 after buying an additional 14,697 shares in the last quarter. Parametrica Management Ltd purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $462,000. Gulf International Bank UK Ltd increased its stake in shares of Vertex Pharmaceuticals by 2.2% in the third quarter. Gulf International Bank UK Ltd now owns 73,692 shares of the pharmaceutical company’s stock valued at $6,426,000 after buying an additional 1,600 shares in the last quarter. Capstone Asset Management Co. increased its stake in shares of Vertex Pharmaceuticals by 1.9% in the third quarter. Capstone Asset Management Co. now owns 24,291 shares of the pharmaceutical company’s stock valued at $2,118,000 after buying an additional 460 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $488,000. Institutional investors own 96.17% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.